About Athira Pharma
Athira Pharma is a company based in Seattle (United States) founded in 2011. Athira Pharma has raised $121.04 million across 13 funding rounds from investors including Franklin Templeton, Citadel and HHS. The company has 26 employees as of December 31, 2024. Athira Pharma operates in a competitive market with competitors including Tenaya Therapeutics, Orca Bio, Avita Medical, Tune Therapeutics and Organogenesis, among others.
- Headquarter Seattle, United States
- Employees 26 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Athira Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$96.94 M (USD)17.62as on Dec 31, 2024
-
EBITDA
-$95.81 M (USD)24.04as on Dec 31, 2024
-
Total Equity Funding
$121.04 M (USD)
in 13 rounds
-
Latest Funding Round
$15 M (USD), Grant
Dec 08, 2020
-
Investors
Franklin Templeton
& 21 more
-
Employee Count
26
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Athira Pharma
Athira Pharma is a publicly listed company on the NASDAQ with ticker symbol ATHA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Athira Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Athira Pharma
Athira Pharma has successfully raised a total of $121.04M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $15 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Athira Pharma
Athira Pharma has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Franklin Templeton, Citadel and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Athira Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Athira Pharma
Investment portfolio details for Athira Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Athira Pharma
Detailed financials for Athira Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Athira Pharma Comparisons
Peer comparison for Athira Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Athira Pharma
Athira Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Orca Bio, Avita Medical, Tune Therapeutics and Organogenesis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Products for regenerative and respiratory medicine are developed and distributed.
|
|
| Locked | Locked | Locked |
Cell and gene therapies are developed via an epigenomic platform.
|
|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
Detailed competitors of Athira Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Athira Pharma
Complete news archive for Athira Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Athira Pharma
Athira Pharma was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Athira Pharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Mark Litton is the current CEO of Athira Pharma.
Athira Pharma is a funded company, having raised a total of $121.04M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Athira Pharma is 26.
Athira Pharma was established in 2011 and is headquartered in Seattle, United States. Operations center on the biotechnology sector, with emphasis placed on developing treatments for neurodegenerative conditions. The primary candidate, Fosgonimeton, targets Alzheimers disease, Parkinsons disease, and multiple dementias. Further assets in the pipeline include ATH-1020, directed at neuropsychiatric disorders, and ATH-1019, aimed at peripheral applications.
Athira Pharma's top competitors include Tenaya Therapeutics, Orca Bio and Avita Medical.
Yes, Athira Pharma is publicly traded on NASDAQ under the ticker symbol ATHA.
Athira Pharma has 22 investors. Key investors include Franklin Templeton, Citadel, HHS, Alzheimer’s Association, and RTW Investments.
The ticker symbol of Athira Pharma is ATHA on NASDAQ.